文献速递头颈外科咽喉与嗓音

口咽鳞癌长期生存者迟发性下组颅神经病变风险及临床危险因素

Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2021-01-01

该单中心队列研究纳入2000至2013年完成根治性治疗的无病口咽鳞癌成人幸存者2021例,中位生存6.8年。随访发现88例(4.4%)发生迟发性下组颅神经病变(LCNP),中位发生时间5.4年,5年、10年、15年累积发生率分别为0.024、0.061、0.098。多因素分析显示T4分期和加速放疗分次独立相关,非手术亚组中TPF方案及TPF联合西妥昔单抗亦相关。

要点

  • T4分期和加速放疗分次是迟发性LCNP的独立危险因素。
  • 非手术患者中TPF方案及TPF联合西妥昔单抗与LCNP风险相关。

核心结论

  • 迟发性LCNP总体罕见,但累积风险在幸存者一生中可进展至约10%。
  • 与LCNP相关的临床因素主要反映更大的肿瘤负荷和更高的治疗强度。

研究设计与样本

  • 单中心队列研究,纳入2000年1月1日至2013年12月31日完成根治性治疗的无病口咽鳞癌成人幸存者2021例。
  • 中位生存6.8年(范围0.3-18.4年),排除基线LCNP、复发、外院治疗、死亡及治疗后3个月内第二原发或持续/复发头颈恶性肿瘤者。
  • 迟发性LCNP定义为癌症治疗后至少3个月出现舌咽、迷走和/或舌下颅神经病变。

主要发现

  • 2021例中88例(4.4%)诊断迟发性LCNP,中位发生时间5.4年(范围0.3-14.1年)。
  • LCNP累积发生率:5年0.024(95%CI 0.017-0.032),10年0.061(95%CI 0.048-0.078),15年0.098(95%CI 0.075-0.128)。
  • 多因素Cox回归显示T4 vs T1分类(HR 3.82;95%CI 1.85-7.86)和加速 vs 标准放疗分次(HR 2.15;95%CI 1.34-3.45)与迟发性LCNP独立相关。
  • 非手术亚组1986例中,含多西他赛、顺铂和氟尿嘧啶的诱导化疗方案(TPF)(HR 2.51;95%CI 1.35-4.67)及TPF联合西妥昔单抗(HR 5.80;95%CI 1.74-19.35)与迟发性LCNP相关。

临床怎么用

  • 对长期口咽鳞癌幸存者,尤其T4分期或接受加速放疗、含TPF诱导化疗者,应关注迟发性下组颅神经病变的监测。
  • 随访中需评估吞咽相关生活质量和相关症状,以便早期发现LCNP。

局限性

  • 单中心队列研究,结果外推需谨慎。
  • 迟发性LCNP事件数较少(88例),部分亚组分析精度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lower cranial neuropathy (LCNP) is a rare, but permanent, late effect of radiotherapy and other cancer therapies. Lower cranial neuropathy is associated with excess cancer-related symptoms and worse swallowing-related quality of life. Few studies have investigated risk and clinical factors associated with late LCNP among patients with long-term survival of oropharyngeal squamous cell carcinoma (OPSCC survivors). OBJECTIVE: To estimate the cumulative incidence of and identify clinical factors associated with late LCNP among long-term OPSCC survivors. DESIGN, SETTING, AND PARTICIPANTS: This single-institution cohort study included disease-free adult OPSCC survivors who completed curative treatment from January 1, 2000, to December 31, 2013. Exclusion criteria consisted of baseline LCNP, recurrent head and neck cancer, treatment at other institutions, death, and a second primary, persistent, or recurrent malignant neoplasm of the head and neck less than 3 months after treatment. Median survival of OPSCC among the 2021 eligible patients was 6.8 (range, 0.3-18.4) years. Data were analyzed from October 12, 2019, to November 13, 2020. MAIN OUTCOMES AND MEASURES: Late LCNP events were defined by neuropathy of the glossopharyngeal, vagus, and/or hypoglossal cranial nerves at least 3 months after cancer therapy. Cumulative incidence of LCNP was estimated using the Kaplan-Meier method, and multivariable Cox proportional hazards models were fit. RESULTS: Among the 2021 OPSCC survivors included in the analysis of this cohort study (1740 [86.1%] male; median age, 56 [range, 28-86] years), 88 (4.4%) were diagnosed with late LCNP, with median time to LCNP of 5.4 (range, 0.3-14.1) years after treatment. Cumulative incidence of LCNP was 0.024 (95% CI, 0.017-0.032) at 5 years, 0.061 (95% CI, 0.048-0.078) at 10 years, and 0.098 (95% CI, 0.075-0.128) at 15 years of follow-up. Multivariable Cox proportional hazards regression identified T4 vs T1 classification (hazard ratio [HR], 3.82; 95% CI, 1.85-7.86) and accelerated vs standard radiotherapy fractionation (HR, 2.15; 95% CI, 1.34-3.45) as independently associated with late LCNP status, after adjustment. Among the subgroup of 1986 patients with nonsurgical treatment, induction chemotherapy regimens including combined docetaxel, cisplatin, and fluorouracil (TPF) (HR, 2.51; 95% CI, 1.35-4.67) and TPF with cetuximab (HR, 5.80; 95% CI, 1.74-19.35) along with T classification and accelerated radiotherapy fractionation were associated with late LCNP status after adjustment. CONCLUSIONS AND RELEVANCE: This single-institution cohort study found that, although rare in the population overall, cumulative risk of late LCNP progressed to 10% during the survivors' lifetime. As expected, clinical factors associated with LCNP primarily reflected greater tumor burden and treatment intensity. Further efforts are necessary to investigate risk-reduction strategies as well as surveillance and management strategies for this disabling late effect of cancer treatment.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Aggarwal P, Goepfert RP, Garden AS, et al. Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 33538759. doi:10.1001/jamaoto.2020.5269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。